CompletedNot Applicable

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

United States78 participantsStarted 2010-02

Plain-language summary

This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with follicular lymphoma in the laboratory may help doctors predict how well patients will respond to treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Untreated follicular lymphoma * Has received rituximab-containing monoclonal antibody therapy on CALGB-50402 or CALGB-50701 * Patients have previously provided informed consent allowing correlative studies on genomic DNA

What they're measuring

overall response

Timeframe: Baseline

Trial details

NCT IDNCT01057459

SponsorAlliance for Clinical Trials in Oncology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2014-06-23

View on ClinicalTrials.gov More Lymphoma trials